الفهرس 
Introduction & aim of the workOnly 14 pages are availabe for public view
 |  | from | 124 |  |  |
| | | from | 124 | | |
Abstract
During the period of January 2021–September 2022, the Family Medicine Department at Minia University Hospital collaborated with the Clinical Pathology Department to conduct the present prospective, analytic hospital-based research.
Identifying the link between MAFLD and a potentially litigable condition was the focus of this research.
Patients with MAFLD illness were chosen at random from those who were being seen in the Internal Medicine Clinic at Minia University Hospital.
One hundred and twenty people with MAFLD participated in our research, and they were matched against a control group of one hundred people who did not have the disease.
All participants had their medical records reviewed, had a comprehensive physical examination, and were subjected to a battery of laboratory tests, including a complete blood count (CBC).
- Unpredictable blood sugar.
- Evaluation of renal function.
Checks of liver function.
INR and prothrombin levels.
Viral biomarkers, including those for HCV and HBV.
The C-Protein.
The S-Protein.
ATG III Anti-Thrombin.
Anti-Platelet Activator Inhibitor Type I.
• A diagnostic imaging battery that includes an abdominal ultrasound.
- MRI.
The following information was found as a result of this study:
The people in the research are evenly distributed across age and gender. Higher rates of hypertension (as measured by both systolic and diastolic blood pressure) and diabetes mellitus were seen among our MAFLD patients compared to healthy controls (P0.oo1). The serum and prothrombin concentrations of MAFLD patients are also much lower than those of controls, but the levels of creatinine & blood urea are significantly greater. In addition, the serum transaminases ALT and AST in our patient group are much higher than in controls (P0.001). Protein C, Elevated Plasma, and Antithrombin III levels were all considerably lower in our MAFLD patients compared to the control group, but PAI-1 levels were significantly greater. Based on the results of a multiple discriminant functional analysis, we know that systolic blood pressure, body mass index, alanine aminotransferase, bile, protein S, antithrombin III, and plasminogen activator inhibitor-1 are all significant predictors of MAFLD The diagnostic accuracy and AUC of a discriminant prediction score for MAFLD both came in at a perfect 100%.